SELL Fortis Healthcare — Rajesh Palviya, Axis Securities
byRajesh Palviya, Axis SecuritiesHorizon: NA (inferred Intraday)8 Jul 2026, 1:01 pm ISTvia CNBC Awaaz.
Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.
AI Assessment
Automated market context for this SELL call — facts from public sources, machine-classified. Not investment advice.
Nothing found in this tip’s window yet.
Nothing found in this tip’s window yet.
Dr. Ashutosh Raghuvanshi has been appointed as the Managing Director & CEO of Fortis Healthcare Limited, effective March 19, 2027.
NSE · Appointment·8 Jul · today
Fortis Healthcare's Board recommended the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and CEO for two years, effective March 19, 2027. He is not debarred from capital markets.
BSE · Company Update·8 Jul · today
Fortis Healthcare Limited's board meeting confirmed the re-appointment of Dr. Ashutosh Raghuvanshi as Managing Director and Chief Executive Officer.
NSE · Outcome of Board Meeting·8 Jul · today
1 advisor has an active swing BUY call on this stock, issued in the last 14 days
Advisor consensus · adjacent horizon·6 Jul · 2d ago
Fortis Healthcare is entering Odisha by signing an Operations & Maintenance agreement with Dion Group for a new 300-bed multi-specialty hospital in Cuttack.
NSE · Press Release·3 Jul · 4d ago
Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.
Other calls on Fortis Healthcare
- SELL — Manas Jaiswal14 Oct 2026 · ~2 weeks · target ₹660 · Active
- BUY — HSBC Securities9 Oct 2026 · ~1 year · target ₹950 · Active
- SELL — Mahesh Ojha, Kantilal Chhaganlal Securities27 Sept 2026 · ~2 weeks · target ₹820 · Target hit
- SELL — Manas Jaiswal25 Sept 2026 · ~2 weeks · target ₹825 · Target hit
- BUY — Nomura India Research7 Sept 2026 · ~1 year · target ₹1,030 · Active
More from Rajesh Palviya, Axis Securities
- BUY Sansera Engineering8 Oct 2026 · ~2 weeks · target ₹4,350 · SL hit
- BUY Trent8 Oct 2026 · ~2 weeks · target ₹3,050 · SL hit
- SELL Sun Pharmaceutical Industries5 Oct 2026 · ~3 months · target ₹1,720 · SL hit
- BUY Cipla29 Sept 2026 · ~2 weeks · target ₹1,480 · SL hit
- BUY Zydus Lifesciences29 Sept 2026 · ~2 weeks · target ₹1,280 · SL hit

